Calcific aortic valve disease (CAVD) is a highly prevalent, disabling and costly disorder with generally poor long-time outcomes once critical stenosis presents with symptoms. Elucidating viable therapeutic strategies for CAVD is pressing. Valvular interstitial cells (VICs) control the structure and function of aortic valve. Intra-leaflet haemorrhage (IH), commonly occurring in histologically stenotic aortic valves, while, in 2019, researchers pointed that iron deposits also presented obviously healthy valves. In line with this, later exploration from vitro showed that iron stimulation alone could not promote VICs calcification. Iron deficiency (ID) is a frequent co-morbidity in multiple chronic cardiovascular diseases such as CAVD; up to 50% of patients with severe aortic stenosis present ID. Data from a small clinical study in patients undergoing TAVI showed those in ID status appeared much higher mean transaortic gradient; whereas no studies have assessed the correlation between ID and aortic valve remodelling and dysfunction progress itself. Here, the investigators aim to investigate for a tentative correlation between ID and human aortic valve remodeling and dysfunction.

Start Date01 Jan 2024

Sponsor / Collaborator

Qilu Hospital of Shandong University

NCT06153407 / RecruitingNot ApplicableIIT

Genetic Test Based Risk Prediction of Early Calcific Aortic Valve Disease in Patients With Bicuspid Aortic Valve

This study is to elucidate the impact of germline mutations and clonal hematopoiesis (CHIP) on the progression of early aortic valve calcification in patients with bicuspid aortic valves. The study will be conducted over a recruitment period of one year and a follow-up observation period of two years. Considering a 2-year event rate and a 33% occurrence rate of clonal hematopoiesis, each group requires a minimum of 102 participants. Accounting for a 15% dropout rate, a total of 120 participants are needed for each group (type I error (α) = 5%, type II error (β) = 20%). Therefore, the total study population, including patients with normal aortic valve function, is set at 240 participants.

Start Date19 Oct 2023

Sponsor / Collaborator

Yonsei University

NCT06194526 / Enrolling by invitationNot ApplicableIIT

Whole Blood Transcriptomic Signal According to Coronary Atherosclerotic Plaque Burden Assessed by CT Angiography: CORPLAQ-TRAIT Pilot Study

The present clinical study aims to identify transcriptomic patterns derived from whole blood samples related to coronary atherotic burden. Additionally, as a secondary analysis, the research team will explore the algorithm's ability to detect the presence of aortic disease and pro-inflammatory cardiometabolic alterations, such as hepatic steatosis and surrogate markers of coronary inflammation.

Start Date19 Sep 2023

Sponsor / Collaborator-

100 Clinical Results associated with Aortic Valve, Calcification Of

100 Translational Medicine associated with Aortic Valve, Calcification Of

0 Patents (Medical) associated with Aortic Valve, Calcification Of

2,299

Literatures (Medical) associated with Aortic Valve, Calcification Of

23 Feb 2024·European journal of preventive cardiology

Prognostic Significance of Aortic Valve Calcification in Relation to Coronary Artery Calcification for Cardiovascular Diseases.

Article

Author: Han Wen ; Rihua Huang ; Xinghao Xu ; Zhenyu Xiong ; Menghui Liu ; Yue Guo ; Xiaodong Zhuang ; Xinxue Liao

AIMS:

Both coronary artery calcification (CAC) and aortic valve calcification (AVC) are strongly associated with cardiovascular diseases (CVD), but data about the prognostic significance of multiple cardiovascular calcifications are limited. We aim to investigate the interaction relationship of AVC and CAC for major events.

METHODS:

We included 6,695 participants from the Multi-Ethnic Study of Atherosclerosis at baseline, and divided them into four groups: 1) no AVC or CAC; 2) only AVC; 3) only CAC; 4) with CAC and CAC. Cox regression model and Kaplan-Meier method were used to analyze CVD outcomes. We evaluated the interaction between AVC and CAC, and their added predictive value based on the pooled cohort equations (PCEs). The subgroup analyses were also explored.

RESULTS:

Among 6,695 participants (mean age 62.2 ± 10.2 years, 47.2% male), after follow-up, 943 cases (14.1%) of CVD and 1274 cases (19.0%) of all-cause death occurred. For participants with both AVC and CAC, the risk of CVD significantly increased {HR =3.43 (2.69-4.37), P <0.001}, even higher than the sum of the ones with only AVC and only CAC. This trend remained the same for all-cause death and among subgroup analysis. The addictive interaction was statistically significant (P <0.001). When added AVC and CAC, the predictive value of PCEs increased.

CONCLUSIONS:

Our results indicated a synergistical interaction between valve calcification and coronary calcification to cardiovascular diseases. Management for both AVC and CAC may bring health co-benefits in preventing poor outcomes.

20 Feb 2024·British journal of pharmacology

Andrographolide regulates H3 histone lactylation by interfering with p300 to alleviate aortic valve calcification.

Article

Author: Chunli Wang ; Shunshun Wang ; Zijun Wang ; Juanjuan Han ; Nan Jiang ; Linghang Qu ; Kang Xu

BACKGROUND AND PURPOSE:

Our previous studies have found that andrographolide (AGP) alleviates calcific aortic valve disease (CAVD), but the underlying mechanism is unclear. This study explores the molecular target and signal mechanisms of AGP in inhibiting CAVD.

EXPERIMENTAL APPROACH:

The anti-calcification effects of the aortic valve with AGP treatment were evaluated by alizarin red staining in vitro and ultrasound and histopathological assessment of a high-fat (HF)-fed ApoE^-/- mouse valve calcification model. A correlation between the H3 histone lactylation (H3Kla) and calcification was detected. Molecular docking and surface plasmon resonance (SPR) experiments were further used to confirm p300 as a target for AGP. Overexpression (oe) and silencing (si) of p300 were used to verify the inhibitory effect of AGP targeting p300 on the H3Kla in vitro and ex vivo.

KEY RESULTS:

AGP significantly inhibited calcium deposition in valve interstitial cells (VICs) and ameliorated aortic valve calcification. The multi-omics analysis revealed the glycolysis pathway involved in CAVD, indicating that AGP interfered with lactate production by regulating lactate dehydrogenase A (LDHA). In addition, lactylation, a new post-translational modification, was shown to have a role in promoting aortic valve calcification. Furthermore, H3Kla and H3K9la site were shown to correlate with Runx2 expression inhibition by AGP treatment. Importantly, we found that p300 transferase was the molecular target of AGP in inhibiting H3Kla.

CONCLUSIONS AND IMPLICATIONS:

Our findings, for the first time, demonstrated that AGP alleviates calcification by interfering with H3Kla via p300, which might be a powerful drug to prevent CAVD.

19 Feb 2024·Animal models and experimental medicine

A novel mouse model of calcific aortic valve stenosis.

Article

Author: Ningjing Qian ; Yaping Wang ; Wangxing Hu ; Naifang Cao ; Yi Qian ; Jinyong Chen ; Juan Fang ; Dilin Xu ; Haochang Hu ; Shuangshuang Yang ; Dao Zhou ; Hanyi Dai ; Dongdong Wei ; Jian'an Wang ; Xianbao Liu

BACKGROUND:

Calcific aortic valve stenosis (CAVS) is one of the most challenging heart diseases in clinical with rapidly increasing prevalence. However, study of the mechanism and treatment of CAVS is hampered by the lack of suitable, robust and efficient models that develop hemodynamically significant stenosis and typical calcium deposition. Here, we aim to establish a mouse model to mimic the development and features of CAVS.

METHODS:

The model was established via aortic valve wire injury (AVWI) combined with vitamin D subcutaneous injected in wild type C57/BL6 mice. Serial transthoracic echocardiography was applied to evaluate aortic jet peak velocity and mean gradient. Histopathological specimens were collected and examined in respect of valve thickening, calcium deposition, collagen accumulation, osteogenic differentiation and inflammation.

RESULTS:

Serial transthoracic echocardiography revealed that aortic jet peak velocity and mean gradient increased from 7 days post model establishment in a time dependent manner and tended to be stable at 28 days. Compared with the sham group, simple AVWI or the vitamin D group, the hybrid model group showed typical pathological features of CAVS, including hemodynamic alterations, increased aortic valve thickening, calcium deposition, collagen accumulation at 28 days. In addition, osteogenic differentiation, fibrosis and inflammation, which play critical roles in the development of CAVS, were observed in the hybrid model.

CONCLUSIONS:

We established a novel mouse model of CAVS that could be induced efficiently, robustly and economically, and without genetic intervention. It provides a fast track to explore the underlying mechanisms of CAVS and to identify more effective pharmacological targets.

News (Medical) associated with Aortic Valve, Calcification Of

04 Jan 2024

·www.prnewswire.com

Little (a), Big Risk: G3 Therapeutics Sets Out to Unravel Lp(a)-Driven Cardiovascular Disease (Lipoprotein(a)-Driven Cardiovascular Disease)

G3 is trailblazing the next frontier of cardiovascular disease SAN FRANCISCO, Jan. 4, 2024 /PRNewswire/ -- G3 Therapeutics ("G3"), a global leader in the use of multiomic biological Big Data, has initiated a groundbreaking initiative to unravel the contribution of Lipoprotein(a) ["Lp(a)"] to cardiovascular disease (CVD). As the treatment of LDL cholesterol has resulted in dramatic improvements in cardiovascular health over the past couple of decades, Lp(a)-driven cardiovascular disease has emerged as the next frontier in cardiovascular medicine. Elevated Lp(a) is the most prevalent genetically determined dyslipidemia and Lp(a)-driven cardiovascular disease may be the most prevalent form of genetically determined CVD. G3's visionary platform, spatial and longitudinal multiomics, anchored in genomics and coupled with deep, precision phenotyping of the cardiovascular system, provides a unique and unprecedented opportunity to unravel the biological mechanisms of Lp(a)-driven CVD. G3 will leverage its propriety data from its own GLOBAL clinical study (NCT01738828) of 7,726 patients, which includes a very large and deep set of measurements. First, the dataset includes extensive phenotyping of Lp(a) and its circulating isoforms, lipids, and lipoproteins. Second, the dataset also includes whole genome sequence data, whole genome methylation, whole transcriptome sequencing, proteomics, metabolomics and lipidomics, data. Finally, all these blood-based measurements are coupled with comprehensive phenotyping of atherosclerosis using cardiovascular computed tomography. Preliminary insights from G3 suggests that Lp(a) is not merely a biomarker; rather, Lp(a)-driven CVD is a distinct, high-risk cardiovascular phenotype, associated with higher atherosclerotic plaque burden, higher risk plaque, and higher prevalence of myocardial infarction. Insights from this comprehensive analysis are expected to have significant clinical implications and will provide scientific basis for identifying the differential role of Lp(a) vs. other lipids and lipoproteins, such as Apolipoprotein B100 (apoB) and LDL-cholesterol, in the development of CVD. Anticipated results from the study will shed light on at least two critical clinical questions: (1) who are the highest risk patients with elevated Lp(a) who will benefit the most from potential future Lp(a)-lowering therapies, and (2) what is the role of elevated Lp(a) in patients with LDL-cholesterol levels already in the optimal range? In addition to atherosclerotic CVD, the project is also investigating the role of Lp(a) in the development of myocardial infarction, as well as in calcific aortic valve stenosis (CAVS). "I have long known of and very much appreciated both the work and immense database developed by the research of the G3 consortium. As a well-recognized clinical and educational lipidologist, I understand the unlimited potential of leveraging their database to better understand and treat complex lipid and lipid/lipoprotein-related disorders. I had the opportunity to work with the G3 team on their novel discoveries related to TG-rich lipoproteins and I eagerly look forward to solving the mysteries / complexities of Lp(a) that I know G3 will uncover.", says Dr. Thomas Dayspring, MD, FACO, FNLA, Lipid Specialist at Early Medical. The scientific initiative is supported by Novartis, and results are anticipated as early as mid-2024 from the initial analyses. About the G3LOBAL Database™ G3 Therapeutic's G3LOBAL Database™ is derived from the GLOBAL clinical study (NCT01738828), an international prospective, multi-center study recruiting up to 10,000 patients to characterize novel disease networks and biomarkers. GLOBAL is the largest and most comprehensive pan-omic study combining whole genome sequencing, whole genome methylation, whole transcriptome sequencing, unbiased proteomics, metabolomics, lipidomics, and lipoprotein proteomics with coronary computed tomographic (CT) angiography, an advanced imaging technology for phenotyping, which allows the precise classification of disease in patients. About G3 Therapeutics G3 Therapeutics is a global leader in the application of unbiased biological big data in transforming the drug discovery and drug development process. G3 Therapeutics has assembled a revelatory platform that utilizes deep phenotyping, deep molecular profiling and deep learning for the discovery, genetic validation, and development of novel drug targets. G3 Therapeutics' foundational biological big data platform has been built on the GLOBAL Clinical Study (NCT01738828), enrolling over 7,500 individuals from around the world. G3 Therapeutics' deep molecular profiling approach includes whole genome sequencing, as well as the measurement of all other relevant "omics" measurements including DNA methylation, RNA sequencing, proteomics, metabolomics, and lipidomics. G3 Therapeutics has already discovered and patented relevant biomarkers and is starting the development of several novel drugs based on its proprietary platform and discoveries. For additional information, please visit SOURCE G3 Therapeutics

15 Nov 2023

·www.biospace.com

Cardiawave Announces the Publication in The Lancet of First-In-Human Clinical Studies Results With 40 Aortic Stenosis Patients Treated With Its Innovative Non-invasive Ultrasound Therapy (NIUT)

Non-Invasive Ultrasound Therapy (NIUT) is feasible and safe. Hemodynamic and clinical improvements statistically demonstrated in high-risk patients with calcific aortic stenosis (CAS). Patients experienced a considerable improvement in their quality of life. A valve repair option bringing a new medical breakthrough to millions of people suffering from CAS in the world. These results and the completion of patients’ enrolment in the pivotal study pave the way for CE marking of the device. Major milestone reached : successful treatment of 100 patients at 12 investigational centers in 4 countries. LEVALLOIS-PERRET, France--(BUSINESS WIRE)-- Cardiawave SA, a French Medtech which has developed an innovative Non-Invasive focused Ultrasound Therapy device for the treatment of calcific aortic stenosis, announced today the publication of results from its First-In-Human (FIH) clinical studies on 40 patients suffering from CAS treated with its NIUT in The Lancet and the completion of the enrollment of 60 patients in its “Valvosoft® pivotal study”. First-In-Human « Valvosoft® FIM Study » results published in The Lancet: (23)01518-0/fulltext These clinical studies’ series entitled “Prospective, controlled, single-arm clinical investigation for the treatment of subjects with severe symptomatic aortic valve stenosis using Valvosoft® Pulsed Cavitational Ultrasound Therapy (PCUT) – First-In-Man” (Coordinating Investigator: Prof. Emmanuel Messas, MD, PhD, FESC, Cardiologist at Hôpital Georges Pompidou AP-HP in Paris, France) enrolled 40 patients with severe symptomatic aortic valve stenosis at 3 clinical sites in France (Hôpital Européen Georges Pompidou, AP-HP, Paris), in the Netherlands (Amphia Hospital, Breda), and in Serbia (University Clinical Center of Serbia, Belgrade). The patients were treated with Cardiawave’s NIUT investigational device in one session. Follow-ups were scheduled at 1, 3, 6, 12, and 24 months. Six-month data are reported in the publication. The primary endpoints were met with no procedure-related mortality through 30 days and improved valve function. No procedure-related mortality occurred; furthermore, no life-threatening or cerebrovascular events were reported. Improved valve function was confirmed at 6 months, reflected by a 10% increase in mean aortic valve area and by quality-of-life improvements. The New York Heart Association (NYHA) score improved or stabilized in 96% of patients (n=24), and the mean Kansas City Cardiomyopathy Questionnaire (KCCQ) score improved by 33%. “Results from this FIH series with a cohort of very frail patients suggest that the use of Non-Invasive Ultrasound Therapy (NIUT) is feasible and safe, and efficient with statistically significant improvements of hemodynamic and clinical parameters in high-risk patients with calcific aortic stenosis (CAS).” said Professor Roxana Mehran, MD, PhD, FACC, FACP, FCCP, FESC, FAHA, FSCAI, Cardiologist, Mount Sinai, New York, NY, USA and member of Cardiawave scientific advisory board. “Clinically, the patients experienced a considerable improvement in their clinical status suggesting a better quality of life. These early findings can represent a change in the paradigm of CAS treatment especially for patients who have no other options. I am encouraged by the momentum of these study results as I anticipate that this therapy potentially brings a new medical breakthrough to many patients suffering from CAS in the world.” End of patients’ enrollment in “Valvosoft® Pivotal Study” In June 2022, following the positive results of our FIH clinical studies, Cardiawave started a pivotal study on severe symptomatic aortic valve stenosis patients who refuse (in Germany and Netherland) or were not recommended for valve replacement. In July 2023, Cardiawave successfully completed the patient enrolment with no procedure or device-related mortality up to 30 days. The study, entitled "Prospective, Single-arm Pivotal Study for the Treatment of Subjects with Severe Symptomatic Calcific Aortic Valve Stenosis Using Valvosoft® Non-Invasive Ultrasound Therapy", successfully enrolled 60 patients at 11 clinical sites in France, Germany and the Netherlands and marks a significant milestone in the development of Cardiawave's medical advances, paving the way for CE marking of the device. Cardiawave would like to express its gratitude to the patients who took part in this clinical study, and to the medical teams and researchers who helped make it possible. The company is committed to continuing its efforts to advance healthcare in the field of cardiology and improve patients' quality of life. What’s next? After the successful treatment of 100 patients at 12 investigational centers in 4 countries, Cardiawave is preparing a Series B financing round which will enable the company to prepare the scale up, the market access in Europe and the launch of its clinical developments in the United States of America as part of the pre-market approval by the Food and Drug Administration (FDA). About Valvosoft® This is a non-invasive ultrasound therapy investigational medical device for the treatment of calcific aortic stenosis developed by Cardiawave. This device uses a new and unique non-invasive transthoracic ultrasound technology that delivers shockwaves on the aortic valve through the cavitation phenomenon. Ultrasound softens the tissue, restores leaflet mobility, and enables a wider opening of the valve. It is currently undergoing clinical investigations for safety and efficacy. It has not yet received any marketing authorization (e.g. CE Marking) and is intended exclusively for clinical investigations. Cardiawave has developed its new breakthrough technology following the work of the prestigious French academic laboratories Institut Langevin (INSERM/CNRS/ESPCI) and Physics for Medicine Paris (INSERM/CNRS/ESPCI/PSL). This non-invasive treatment of aortic stenosis combines therapeutic ultrasound, robotics, and ultrasound imaging. All software and most hardware components have been developed in-house thanks to the unique know-how of Cardiawave and its academic partners. About CALCIFIC AORTIC STENOSIS Calcific aortic stenosis (CAS) is a degenerative and potentially life-threatening condition, caused by calcium buildup which prevents the aortic valve from fully opening. Aortic Stenosis (AS) evolves over time leading to heart failure and increases the risk of sudden death during its final stage (severe & symptomatic stenosis). AS has become a public health issue as the pathology affects between 1,7 and 12,4% of subjects over 75 years old (sources: Durko AP, et al. Annual number of candidates for transcatheter aortic valve implantation per country: current estimates and future projections. European Heart Journal. July 01, 2018; 39(28):2635-2642. (DOI: 10.1093/eurheartj/ehy107); Lindman B, et al. Calcific Aortic Stenosis. Nature Reviews Disease Primers 2, Article number: 16006. March 03, 2016. (DOI: 10.1038/nrdp.2016.6); Osnabrugge R., et al. Aortic Stenosis in the Elderly: Disease Prevalence and Number of Candidates for Transcatheter Aortic Valve Replacement: A Meta-Analysis and Modeling Study. Journal of American College of Cardiology, Volume 62, Issue 11, Pages 1013-1014. September 2013. (DOI: 10.1016/j.jacc.2013.05.015). With age, the aortic valve calcifies, becomes more rigid and narrow, and no longer opens properly leading to poor blood circulation. AS can be mild, moderate, and severe. 2 million people are estimated to suffer from severe AS in Europe and in the USA, of whom 500,000 per year benefit from Transcatheter Aortic Valve Replacement (TAVR) or open-heart surgery. 1.5 million patients remain untreated and face a low life expectancy of 2 to 5 years. Around 3 million further patients suffer from moderate AS for whom there is no early treatment. About CARDIAWAVE Cardiawave has developed a Non-Invasive Ultrasound Therapy (NIUT) medical device for the treatment of valvular heart diseases, and in particular, CAS, the most prevalent heart valve disease in adults and one of the most common causes of cardiovascular mortality worldwide. Based near Paris, Cardiawave is a member of the national research consortium RHU Stop-AS, and has EN ISO 13485:2016 certification since 2019. Cardiawave employs 30 people and has secured over 29M€ in funding since its creation in 2014. This project was supported by the Program “Investissements d’Avenir” as part of the World Innovation Competition. It also benefited from state aid managed by the National Research Agency under the references ANR-16-RHUS-0003_STOP-AS and ANR-17-CE19- 0019-03 and the Horizon 2020 SME instruments program of the European Commission (reference no. 829492). Cardiawave is a winner of the French Tech Health 20 programme and a member of La French Care since 2023. Learn more: View source version on businesswire.com: Contacts Cardiawave Maurice Delplanque – CEO cw-ceo@cardiawave.com +33 (0)1 55 26 82 20 Contacts presse Stéphanie Lentini - slentini@gmail.com +33 (0)7 62 62 51 21 Source: Cardiawave View this news release online at:

Clinical ResultClinical Study

04 Jul 2023

·www.prnewswire.com

Microphysiological Systems Conference 2023: A Deep Dive into Technologies & Applications - Innovations in 3D-Culture, Organoids, and Organs-on-Chips fields (Orlando, Florida - July 26-27, 2023)

DUBLIN, July 3, 2023 /PRNewswire/ -- The "Microphysiological Systems 2023: A Deep Dive into Technologies & Applications" conference has been added to ResearchAndMarkets.com's offering. Welcome to the Microphysiological Systems 2023: A Deep Dive into Technologies & Applications to be held July 26-27, 2023 in Orlando, Florida This conference brings together the innovations in 3D-Culture, Organoids, and Organs-on-Chips fields, circa 2023, and brings the key opinion leaders and thought leaders in the field for an intensive 2-days of scientific presentations, networking as well as engagement with companies developing innovations in tools and technologies in this expanding space. This conference brings together researchers from both academia and industry and will discuss the development of techniques and tools implemented in the study and analysis of 3D-Culture, Organoids and Organs-on-Chips systems utilizing BioEngineering Tools and Technologies. Topics to be covered include 3D-cell based screening methods, high content screening, and analysis, the use of model systems, and novel approaches for physiologically-relevant analysis of cell systems as well as building these systems (MPS systems). Attending this event will provide you with excellent opportunities for networking with attendees from biotech companies, academia, and technology/tools vendors, helping you to find solutions and build collaborations. The host is honored that Professor Mike Shuler, Samuel B. Eckert Professor of Engineering at Cornell University and President of Hesperos will be Chairperson of this Conference. Conference Attendees Receive Full Access to the Co-Located EV Conference for Maximal Networking and Scientific Exchange. **The Conference Features Scientific Presentations from Academics, Technical Presentations from Industry, Technology Spotlight Presentations from Technology-Tools Vendors, and an Exhibit Hall with Companies Showcasing their Commercial Offerings.** Agenda Topics BioEngineering Approaches for Building Microphysiological Systems/Organs-on-a-Chip Building Microphysiological Systems -- Organs-on-a-Chip Technologies and Tools in this Space End-User Applications of Microphysiological Systems Currently, circa 2023 High-Content Analysis and Phenotypic Screening and Analysis in 3D-Culture, Organoids and Organs-on-Chips Model Systems Organ-on-a-Chip Applications for Drug Discovery and Toxicity Screening Organ-on-a-Chip/Body-on-a-Chip Assembly using Microfluidics: Tools and Approaches Agenda: Wednesday, 26 July 2023 08:00 - Conference Registration and Materials Pick-Up + Coffee Session Title: Emerging Trends and Themes in the Microphysiological Systems (MPS) Space Session Chairperson: Professor Mike Shuler, Cornell University and Hesperos 09:00 - Michael Shuler - Conference Chair Making Microphysiological Systems (MPS) Useful Michael Shuler, Samuel B. Eckert Professor of Engineering, Cornell University, President Hesperos, Inc., United States of America 09:30 - Jason Ekert - Keynote Presentation An Outlook Towards Adoption of MPS in Drug Development Jason Ekert, Head US Discovery Translational Technology, UCB Pharma, United States of America 10:00 - Reyk Horland - Keynote Presentation The Impact of Integrated Multi-Organ-Chip Systems in Substance Testing: Progress and Future Outlook Reyk Horland, CEO, TissUse GmbH, Germany 10:30 - Mid-Morning Coffee Break and Networking in the Exhibit Hall 11:15 - James Hickman - Keynote Presentation Human-on-a-Chip Systems as Pre-Clinical Models for Neurological Diseases and Disorders James Hickman, Professor, Nanoscience Technology, Chemistry, Biomolecular Science and Electrical Engineering, University of Central Florida; Chief Scientist, Hesperos, United States of America 11:45 - Mandy Esch - Keynote Presentation Design and Operation of Pumpless Multi-Organ Microphysiological Devices Mandy Esch, Project Leader, National Institute of Standards and Technology (NIST), United States of America 12:15 - Networking Lunch - Network with Colleagues and Meet Exhibitors 14:00 - Gretchen Mahler - Keynote Presentation Calcific Aortic Valve Disease on a Chip Gretchen Mahler, Professor of Biomedical Engineering, Binghamton University, United States of America 14:30 - Multiorgan Microphysiological Systems as Tools to Study Complex Diseases Martin Trapecar, Assistant Professor, Johns Hopkins University, United States of America 15:00 - Intelligent Droplet Screen for High-Throughput Single Cell Level Tumor Profiling on Extracellular Matrix Chia-Hung Chen, Associate Professor, City University of Hong Kong, Hong Kong 15:30 - Mid-Afternoon Coffee Break and Networking 16:00 - Matthias von Herrath - Keynote Presentation Title to be Confirmed. Matthias von Herrath, Vice President and Senior Medical Officer, Novo Nordisk, Professor, La Jolla Institute, United States of America 16:30 - Tissue Chips in Space: Modeling Human Disease States in Microgravity Dmitriy Krepkiy, Program Officer, National Center for Advancing Translational Sciences (NCATS), United States of America 17:00 - Close of Conference Programming + Networking Reception with Beer and Wine 18:30 - Close of Conference Day Thursday, 27 July 2023 08:00 - Morning Coffee and Networking in the Exhibit Hall 09:00 - Michael Roberts - Keynote Presentation Biomanufacturing and In-Space Production Applications on the ISS National Lab Michael Roberts, Chief Scientific Officer, International Space Station National Laboratory, United States of America 09:45 - Jana Stoudemire - Conference Chair Humanity's Next Chapter Jana Stoudemire, Director, In-Space Manufacturing, Axiom Space, United States of America 10:30 - Morning Coffee Break and Networking in the Exhibit Hall 11:15 - Marc Giulianotti - Conference Chair The Orbital Age Marc Giulianotti, Sr. Manager, In Space Biomanufacturing, Sierra Space, United States of America 12:00 - DNA-Inspired Janus Base Nanomaterials for Cartilage Tissue Chip Applications Yupeng Chen, Associate Professor, University of Connecticut, United States of America 12:30 - Applying Analytics to Muscle Tissue Chip Real-Time Biomechanics for In-Space Biomonitoring of Tissue Degradation Siobhan Malany, Associate Professor, University of Florida and Founder, Micro-gRx, United States of America 13:00 - Networking Luncheon in the Exhibit Hall -- Network with the Exhibitors and Engage with Colleagues For more information about this conference visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Analysis

Perform a panoramic analysis of this field.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Aortic Valve, Calcification Of

Basic Info

Related

Analysis